Literature DB >> 8326184

Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India.

D N Lockwood1, S Vinayakumar, J N Stanley, K P McAdam, M J Colston.   

Abstract

A retrospective survey of the notes on all patients attending Dhoolpet Leprosy Research Center, India, during 1985 was done to establish the frequency, timing, and clinical features of reversal (type 1) reactions; 494 case notes were examined and clinical evidence of a reversal reaction was found in 44 cases (10.9%). Reactions were most common in borderline patients, with 11.4% and 14.8% of borderline tuberculoid (BT) and borderline lepromatous (BL) patients developing reactions, respectively. Presentation in reaction was frequent with 47.5% of reactional patients having signs of a reversal reaction at the time of their first visit to the Dhoolpet clinic; 50% of skin reactions developing in patients on antileprosy treatment occur within the first month of treatment. Neurological reactions occur later and over a longer time course. Late reactions may occur up to 6 1/2 years after the start of treatment. Further reactional episodes occurred in 31.8% of the patients, and may be repeated. Steroid treatment produced improvement of both skin lesions and neuritis, but improvement in clinical signs and symptoms occurred in only 50% of the neuritic episodes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326184

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  16 in total

1.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

Review 2.  Recent advances in tropical medicine.

Authors:  D N Lockwood; G Pasvol
Journal:  BMJ       Date:  1994-06-11

3.  Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment.

Authors:  D Little; S Khanolkar-Young; A Coulthart; S Suneetha; D N Lockwood
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.

Authors:  Anna K Andersson; MeherVani Chaduvula; Sara E Atkinson; Saroj Khanolkar-Young; Suman Jain; Lavanya Suneetha; Sujai Suneetha; Diana N J Lockwood
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factor-beta (TGF-beta) in leprosy lesions.

Authors:  S Khanolkar-Young; D Snowdon; D N Lockwood
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

6.  Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes.

Authors:  Bishwa R Sapkota; Murdo Macdonald; William R Berrington; E Ann Misch; Chaman Ranjit; M Ruby Siddiqui; Gilla Kaplan; Thomas R Hawn
Journal:  Hum Immunol       Date:  2010-08-01       Impact factor: 2.850

Review 7.  Leprosy and the human genome.

Authors:  Elizabeth A Misch; William R Berrington; James C Vary; Thomas R Hawn
Journal:  Microbiol Mol Biol Rev       Date:  2010-12       Impact factor: 11.056

8.  Electro-physiological evaluation of nerves during reactions in leprosy.

Authors:  A K Thacker; S Chandra; R D Mukhija; N B Sarkari
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

Review 9.  Understanding the type 1 reactional state for early diagnosis and treatment: a way to avoid disability in leprosy.

Authors:  José Augusto da Costa Nery; Fred Bernardes Filho; Juliana Quintanilha; Alice Miranda Machado; Soraya de Souza Chantre Oliveira; Anna Maria Sales
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

10.  Serological responses to prednisolone treatment in leprosy reactions: study of TNF-α, antibodies to phenolic glycolipid-1, lipoarabinomanan, ceramide and S100-B.

Authors:  Renuka Raju; Sujai Suneetha; Rupendra S Jadhav; MeherVani Chaduvula; Sara Atkinson; Suman Jain; Leo H Visser; Loretta Das; Ravindra Panhalkar; Vidyagouri Shinde; Parphananda P Reddy; Pramila Barkataki; Diana Nj Lockwood; Wim H Van Brakel; Lavanya M Suneetha
Journal:  Lipids Health Dis       Date:  2014-07-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.